secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUNIC, INC. (IMUX)
CIK:        0001280776
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001193805-23-000659
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunic reports phase 1b IMU-856 data: reduced villous height loss, improved symptoms, no safety issues
--------------------------------------------------------------------------------

- Placebo group had 60.3 µm villous height reduction vs. 20.9 µm (80mg) and 22.5 µm (160mg) for IMU-856 (p=0.04) under gluten challenge.
- On first gluten challenge day, placebo symptom increases (nausea 0.8, pain 0.8, diarrhea 0.8) vs. pooled IMU-856 (0.4, 0.5, 0.6) on 5-point scale.
- Dose-dependent lessening of serum IL-2 release with IMU-856; citrulline levels increased in active arms while decreasing in placebo.
- Vitamin B12 increased by 45.8 pmol/L (80mg) and 74.2 pmol/L (160mg) with IMU-856 vs. 31.0 pmol/L decrease with placebo.
- No serious adverse events; two IMU-856 patients showed Q-Marsh histology improvement despite gluten challenge vs. none on placebo.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1280776/000119380523000659/0001193805-23-000659-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1280776/000119380523000659/e618584_8k-immunic.htm
  HTML page:      https://secwatch.observer/filing/0001193805-23-000659

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer